Alzheimer's Disease
Conditions
Interventions
Control group:None
Sponsors
The Third Affiliated Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 50–85 years; 2. Completed an Amyloid-PET scan within 3 months before and after enrollment; 3. Met the diagnostic criteria for Alzheimer’s disease (AD); 4. The patient or legal guardian provided informed consent to participate in this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals with a history of psychiatric disorders or congenital mental retardation; 2.Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, severe endocrine disorders, severe infectious diseases, or toxic encephalopathy; 3. Patients with other neurological disorders that may cause cognitive impairment, such as stroke, Parkinson’s disease, brain tumors, etc.; 4. Patients with depression; 5.Individuals with a history of head trauma or use of specific medications within the past 6 months; 6. Individuals with confirmed alcohol or drug dependence within the past 6 months; 7.Patients who did not undergo MRI, or those with MRI findings including: Fazekas scale score >= 3 for white matter lesions, 2 or more lacunar infarcts, or lesions located in critical brain regions; 8.Patients who received monoclonal antibody therapy targeting amyloid-beta (Aß) (e.g., aducanumab, lecanemab, donanemab, etc.) prior to enrollment; 9. Patients whose blood test results did not meet the requirements of this study; 10. Patients with incomplete baseline data. Individuals with depression; Individuals with a history of head trauma or special drug use within the past 6 months; Individuals confirmed to have alcohol or drug dependence within the past 6 months; Individuals who have not completed MRI examination, or those with the following lesions detected by MRI: cerebral white matter lesions with a Fazekas scale score = 3, or presence of 2 or more lacunar infarction lesions, or lesions located in key brain regions; Individuals whose blood test criteria do not meet the requirements of this study; Individuals with incomplete baseline data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Aß34 level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Amyloid-PET; | — |
Countries
China
Contacts
Public ContactTianming Lv
The Third Affiliated Hospital of Southern Medical University
Outcome results
None listed